Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
作者信息
Lima Caio M S R
机构信息
Wake Forest School of Medicine, Winston-Salem, North Carolina.
出版信息
Clin Adv Hematol Oncol. 2018 Sep;16 Suppl 17(9):3-5.
PMID:30807559
Abstract
摘要
相似文献
1
2
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Clin Adv Hematol Oncol. 2018 Sep;16 Suppl 17(9):9-10.
3
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Clin Adv Hematol Oncol. 2018 Sep;16 Suppl 17(9):5-7.
4
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Expert Rev Anticancer Ther. 2016 May;16(5):485-92. doi: 10.1080/14737140.2016.1174581. Epub 2016 Apr 22.
5
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Clin Adv Hematol Oncol. 2018 Sep;16 Suppl 17(9):7-9.
6
Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.
Cancer Med. 2024 Jan;13(1):e6582. doi: 10.1002/cam4.6582. Epub 2023 Dec 22.
7
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21.
8
FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Curr Oncol. 2019 Aug;26(4):e466-e472. doi: 10.3747/co.26.4903. Epub 2019 Aug 1.
9
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
Clin Cancer Res. 2021 Sep 15;27(18):5020-5027. doi: 10.1158/1078-0432.CCR-21-0929. Epub 2021 Jul 12.
10
Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Updates Surg. 2020 Jun;72(2):321-324. doi: 10.1007/s13304-020-00798-3.
Zotero 插件